Clinical Effect of Recombinant Human Interferon α1b in the Adjuvant Treatment of Asthmatic Bronchitis In Children
Objective To explore the clinical effect of recombinant human interferon α1b in the adjuvant treatment of asthmatic bronchitis(AB)in children and its influence on sleep state,RUNt-related transcription factor 3(RUNX3)and T lymphocyte chemokine receptor 3(CXCR3)expression.Methods A total of 106 children with AB in Zhengzhou People's Hospital from February 2020 to July 2023 were selected as the study objects,and were divided into inhalant group and interferon group by random number table method.The inhalant group was treated with conventional nebulized inhalant,and the interferon group was treated with recombinant human interferon α1b.Symptom resolution time,expression of related factors and sleep status were compared between the two groups.Results The disappearance time of cough,wheezing,wheezing and rales in interferon group was shorter than that in inhalant group(P＜0.05).After 1 week of treatment,RUNX3 levels in two groups were higher than before treatment,and those in interferon group were higher than those in inhalant group.CXCR3 levels in interferon group were lower than those in inhalant group(P＜0.05).After 1 week of treatment,the number of awakenings in two groups was less than before treatment,and interferon group was less than inhalant group.The sleep time level of interferon group was longer than that of inhalant group(P＜0.05).Conclusion Recombinant human interferon α1b adjuvant therapy can regulate the expression of related factors in AB children,improve symptoms such as cough and wheezing,and regulate sleep state.
asthmatic bronchitisrecombinant human interferon α1baerosol inhalantssleep state
万方数据
维普
